Sativex Mouth Spray
Medical Marijuana Sativex News & Information
European Medical Marijuana product Sativex is challenged by North America’s … – San Francisco Chronicle (press release)
01 day
|
European Medical Marijuana product Sativex is challenged by North America's …
San Francisco Chronicle (press release) Until now, only two forms of smokeless medical marijuana containing chemicals actually found in the marijuana plant have been on the market, Sativex and Marinol. However, Sativex, an oral spray manufactured by GW Pharmaceuticals and approved in many … |
Man grew cannabis to help him calm his anger problem – Derby Telegraph
01 day
|
Man grew cannabis to help him calm his anger problem
Derby Telegraph Google 'Sativex' and or 'Nabiximols'. Sativex is liquid cannabis in a bottle which is deemed a safe and effective medicine. What is even more amazing is that it hasn't got a schedule under the MoDA and anyone who prescribes it is guilty of supplying a … |
European Medical Marijuana product Sativex is challenged by North America’s New Cannabis Pill Idrasil, Says Doobons
01 day
by Dr. Sativex
in Sativex News
Idrasil, a full-spectrum cannabinoid pill, satisfies the medical community with its standardized 25 mg tablet and changes the way patients and physicians view medical marijuana.San Francisco, CA (PRWEB) May 19, 2012 Doobons.com and Idrasil are discovering that the groundbreaking new medical marijuana pill, Idrasil, is in high demand by patients all over the world who are looking for the benefits …
European Medical Marijuana product Sativex is challenged by North America’s … – DigitalJournal.com (press release)
02 days
|
European Medical Marijuana product Sativex is challenged by North America's …
DigitalJournal.com (press release) Until now, only two forms of smokeless medical marijuana containing chemicals actually found in the marijuana plant have been on the market, Sativex and Marinol. However, Sativex, an oral spray manufactured by GW Pharmaceuticals and approved in many … |
Marijuana may ease multiple sclerosis symptoms
06 days
by Dr. Sativex
in Sativex News
By Amy Norton NEW YORK (Reuters Health) – People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping. And a new clinical trial suggests they are not just blowing smoke. The study, published Monday, found that for 30 MS patients with muscle "spasticity," a few days of marijuana smoking brought some relief. But the big caveat, researchers say, is …
Business week in review – The Independent
08 days
|
Business week in review
The Independent The research & development director at GW Pharmaceuticals confirmed on Tuesday that the group's cannabis-based drug, Sativex, has been approved in 10 more European countries, including Finland, Luxembourg and Slovakia. The medicine, which acts as pain … |
GW Pharma and Almirall complete European MRP for Sativex – pharmabiz.com
011 days
|
GW Pharma and Almirall complete European MRP for Sativex
pharmabiz.com GW Pharmaceuticals plc (GWP) and Almirall SA (ALM), an international pharmaceutical company based on innovation and committed to health, have successfully completed the European Mutual Recognition Procedure (MRP) for Sativex oromucosal spray in the … GW shares get buzz from cannabisThe Independent Ten more approvals for GW Pharma's cannabis sprayPharma Times |
Sativex Mutual Recognition Procedure Closes with Recommendation for Approval … – PharmaLive.com (press release)
012 days
|
Sativex Mutual Recognition Procedure Closes with Recommendation for Approval …
PharmaLive.com (press release) Sativex® is already available in the UK, Spain, Germany and Denmark. Launches currently in preparation in Italy, Sweden, Austria and Czech Republic • Recommendation for approval now received in Belgium, Finland, Iceland, Ireland, Luxembourg, … Ten more approvals for GW Pharma's cannabis sprayPharma Times New cannabis green light lifts GW PharmaEvening Standard |
BRIEF-GW Pharma’s Sativex set for approval in 10 countries – London South East
013 days
|
BRIEF-GW Pharma's Sativex set for approval in 10 countries
London South East The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Datafeed and UK data supplied by NETbuilder and Interactive Data. |
FLASH: GW and Almirall complete MRP for Sativex – Stock Market Wire
013 days
|
FLASH: GW and Almirall complete MRP for Sativex
Stock Market Wire MoneyAM website is aimed at investors of all levels of experience including City professionals, investors and full-time traders. Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is … |
Time: What Is President Obama’s Problem With Medical Marijuana? – Hawaii News Daily
016 days
|
Time: What Is President Obama's Problem With Medical Marijuana?
Hawaii News Daily Some in federal law enforcement–and at the Office of National Drug Control Policy–hope that the advent of new pharmaceutical replacements for grown medical marijuana, like the Canadian drug Sativex, [Editor's note: Sativex is a British drug, … |
What Is President Obama's Problem with Medical Marijuana?
017 days
by Dr. Sativex
in Sativex News
For a brief moment in 2009, medical marijuana advocates exhaled. A new President had taken office promising to call off the federal prosecutors in states that had legalized weed for the sick. "What I'm not going to be doing is using Justice Department resources to try to circumvent state laws on this issue," Barack Obama had said during his presidential campaign. In his first year in office, the …
Why We Need To End The War On Drugs – Tripped Media
020 days
 Tripped Media |
Why We Need To End The War On Drugs
Tripped Media Pharmaceutical company GW Pharma has already won approval in Canada and several European countries for Sativex which includes delta 9-THC and cannabidiol, two of marijuana's main components. So it's okay for pharmaceutical companies to manufacture … |
GW PHARMACEUTICALS PLC : Sativex phase IIb pain trial results publication – 4-traders
027 days
|
GW PHARMACEUTICALS PLC : Sativex phase IIb pain trial results publication
4-traders This Phase IIb study was the first major trial carried out by GW and Otsuka Pharmaceutical as part of the development program aimed at securing regulatory approval for Sativex® from the Food & Drug Administration (FDA) in the United States. Journal of Pain review boost for GW PharmShareCast |
GW announces publication of Sativex trial results – Stock Market Wire
028 days
|
GW announces publication of Sativex trial results
Stock Market Wire StockMarketWire.com – Full Sativex phase IIb pain trial results have been published in the American Pain Society's official journal. The publication in the 'Journal of Pain' was announced by GW Pharmaceuticals and Otsuka Pharmaceutical. |
FLASH: GWP announces publication of Sativex trial results – Stock Market Wire
028 days
|
FLASH: GWP announces publication of Sativex trial results
Stock Market Wire MoneyAM website is aimed at investors of all levels of experience including City professionals, investors and full-time traders. Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is … |
No proof of added benefit of Sativex, says German IQWiG – The Pharma Letter
034 days
|
No proof of added benefit of Sativex, says German IQWiG
The Pharma Letter In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether Sativex, a cannabis-based treatment for moderate … |
MS drug being trialled for cannabis addiction – ABC Online
034 days
|
MS drug being trialled for cannabis addiction
ABC Online Hunter Area Director for Drug and Alcohol Clinical Services Adrian Dunlop says the MS drug Sativex could be the help they're looking for. He says 50 cannabis users are now being sought for the trial in Sydney and Newcastle. "This trial hasn't been done … |
GW confirms €11.9m haul – Business Weekly
034 days
|
GW confirms €11.9m haul
Business Weekly The milestone reflects the revised terms of the expanded collaboration between the UK company and Almirall and recognises the achievement of a specified patient recruitment target in the Sativex® Phase III cancer pain trial programme. |
Weeding out a world of pain – The Nelson Mail
035 days
 The Nelson Mail |
Weeding out a world of pain
The Nelson Mail The cannabis-derived medication Sativex, in the form of an inhaler, is available only for people with multiple sclerosis, to control spasticity where all other medical avenues have been exhausted. However, it's not funded by Pharmac and costs about … |